Alcon Inc (ALC)
67.49
+0.59
(+0.88%)
USD |
NYSE |
Mar 24, 16:00
67.50
+0.01
(+0.01%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 33.08B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -11.24% |
| Valuation | |
| PE Ratio | 100.75 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.829 |
| Price to Book Value | 1.681 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2229 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2357 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
03/23 09:05
Yahoo
03/01 09:03
MT Newswires
02/27 16:39
MT Newswires
02/27 16:38
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/11/2023* | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/10/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 02/28/2023 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/27/2023 | -- | Results | Q4 2022 | 0.42 | 0.42 | -0.98% | |
| 11/16/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/15/2022 | -- | Results | Q3 2022 | 0.50 | 0.48 | 3.56% | |
| 08/10/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/09/2022 | -- | Results | Q2 2022 | 0.63 | 0.56 | 12.60% |
*Estimated Date/Time
Earnings
Profile
Edit
| Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |
| URL | https://www.alcon.com |
| Investor Relations URL | https://investor.alcon.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Feb. 27, 2023 |
| Next Ex-Dividend Date | May. 09, 2023 |
| Last Ex-Dividend Date | May. 03, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.2057 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.218 |
| Yield to Sector | 0.145 |
| Yield to Industry | 0.2753 |
| Last Dividend Amt. | 0.2229 |
| Dividend Frequency | Annually |
| Last Ex-Dividend Date | May. 03, 2022 |
| Yield (TTM) | 0.30% |
| Forward Yield | 0.33% |
| Payout Ratio | 29.85% |
| Cash Payout Ratio | 21.19% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 8.717B |
| Total Expenses (TTM) | 8.045B |
| Net Income (TTM) | 335.00M |
| Total Assets (Quarterly) | 29.21B |
| Total Liabilities (Quarterly) | 9.532B |
| Shareholders Equity (Quarterly) | 19.68B |
| Cash from Operations (TTM) | 1.217B |
| Cash from Investing (TTM) | -1.865B |
| Cash from Financing (TTM) | -8.00M |
Ratings
Profile
Edit
| Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |
| URL | https://www.alcon.com |
| Investor Relations URL | https://investor.alcon.com/ |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | May. 10, 2023 (est.) |
| Last Earnings Release | Feb. 27, 2023 |
| Next Ex-Dividend Date | May. 09, 2023 |
| Last Ex-Dividend Date | May. 03, 2022 |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| BBHLX | 80.23M CHF | 3.51% |
| AGNG | 1.818M CHF | 2.98% |
| BMEZ | 50.24M CHF | 2.53% |
| FLSW | 1.193M CHF | 2.48% |
| JOHAX | 138.37M CHF | 2.40% |
| EWL | 29.47M CHF | 2.39% |
| LMPLX | 193.32M CHF | 2.31% |
| ARTJX | 81.72M CHF | 1.94% |
| APDIX | 99.23M CHF | 1.87% |
| LRGE | 2.312M CHF | 1.83% |
| HLMNX | 236.96M CHF | 1.58% |
| RNDM | 180395.0 CHF | 0.96% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ALC Tweets |